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Background: The aim of this study was to investigate which glycemic parameters better reflect urinary N-acetyl-β-D-
glucosaminidase (uNAG) abnormality, a marker for renal tubulopathy, in subjects with type 2 diabetes mellitus (T2DM) subjects 
with normoalbuminuria and a normal estimated glomerular filtration rate (eGFR). 
Methods: We classified 1,061 participants with T2DM into two groups according to uNAG level—normal vs. high (>5.8 U/g cre-
atinine)—and measured their biochemical parameters. 
Results: Subjects with high uNAG level had significantly higher levels of fasting and stimulated glucose, glycated albumin (GA), 
and glycosylated hemoglobin (HbA1c) and lower levels of homeostasis model assessment of β-cell compared with subjects with 
normal uNAG level. Multiple linear regression analyses showed that uNAG was significantly associated with GA (standardized β 
coefficient [β]=0.213, P=0.016), but not with HbA1c (β=–0.137, P=0.096) or stimulated glucose (β=0.095, P=0.140) after ad-
justing confounding factors. In receiver operating characteristic analysis, the value of the area under the curve (AUC) for renal tu-
bular injury of GA was significantly higher (AUC=0.634; 95% confidence interval [CI], 0.646 to 0.899) than those for HbA1c 
(AUC=0.598; 95% CI, 0.553 to 0.640), stimulated glucose (AUC=0.594; 95% CI, 0.552 to 0.636), or fasting glucose (AUC=0.558; 
95% CI, 0.515 to 0.600). The optimal GA cutoff point for renal tubular damage was 17.55% (sensitivity 59%, specificity 62%). 
Conclusion: GA is a more useful glycation index than HbA1c for reflecting renal tubulopathy in subjects with T2DM with nor-
moalbuminuria and normal eGFR.
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INTRODUCTION
Diabetic kidney disease (DKD) is the leading cause of chronic 
kidney disease (CKD), which results in end-stage renal disease 
in many countries. DKD is also a main cause of diabetes-relat-
ed morbidity and mortality. Therefore, earlier adoption of 
methods to estimate CKD risks along with a more accurate 
glycemic index for patients with type 2 diabetes mellitus 
(T2DM) is highly desirable and could guide physicians in lim-
iting development and progression of DKD. Among the 
known CKD and DKD parameters, albuminuria and estimat-
ed glomerular filtration rate (eGFR) have traditionally been 
considered the best markers of renal glomerular injury and 
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and low eGFR do not secrete significant amounts of albumin-
uria, and an eGFR decrease frequently precedes development 
of microalbuminuria. This indicates that change in the glom-
erulus might be neither the initial step in DKD development 
nor the major determinant of renal prognosis in subjects with 
T2DM. It is now increasingly recognized that tubules play an 
important role in DKD pathogenesis [1]. One of the widely 
used tubular injury markers is N-acetyl-β-D-glucosaminidase 
(NAG), a lysosomal enzyme of renal proximal tubular epitheli-
al cells. Previous studies have demonstrated that urinary NAG 
(uNAG) excretion is also elevated in patients with diabetes 
who still have normoalbuminuria and normal eGFR, which is 
consistent with the view that proximal tubular injury might be 
a measurable component of early DKD [2,3]. Furthermore, we 
previously demonstrated that stimulated glucose and glycated 
albumin (GA), an early Amadori glycated protein of the non-
enzymatic glycation reaction between glucose and serum albu-
min, might be associated with diabetic renal tubulopathy, as 
assessed by uNAG [4]. GA is a well-established glycemic index 
for reflecting glycemic excursions and postprandial hypergly-
cemia compared with glycosylated hemoglobin (HbA1c) [5,6]. 
Furthermore, GA is known to contribute to increased oxida-
tive stress in patients with diabetes since glycation of albumin 
impairs albumin’s antioxidant activities [7]. Considering the 
crucial effects of both glycemic excursion and oxidative stress 
on renal damage, we hypothesize that GA is a better reflector 
of early DKD than HbA1c. However, few studies have investi-
gated the associations between glycemic parameters and renal 
tubular damage in subjects with early-stage DKD.
 Herein, we investigated the associations between various 
glycemic control indices and DKD markers, including the tu-
bular index of uNAG, in T2DM subjects with normoalbumin-
uria and normal eGFR. Additionally, we compared GA with 
other surrogate markers of glycemic parameters, such as 
HbA1c, fasting plasma glucose, and stimulated glucose in 
terms of their ability to predict early tubular dysfunction. 
METHODS
Study subjects
The present study was a retrospective investigation of patients 
with T2DM who visited Severance Hospital Diabetes Center 
between March 2015 and November 2016, Wonju Severance 
Christian Hospital Diabetes Center between October 2016 and 
April 2017, or Samsung Medical Center Diabetes Center be-
tween February 2016 and November 2016. All patients were 
tested for serum GA, HbA1c, and uNAG. They all underwent a 
standardized liquid-meal test. Participants who met the follow-
ing criteria were excluded: <20 years of age, having type 1 dia-
betes mellitus (T1DM), taking a sodium-glucose cotransporter 
2 inhibitor, pregnancy, liver cirrhosis, urine albumin-to-creati-
nine ratio (ACR) ≥30 mg/g, or eGFR <60 mL/min/1.73 m2. A 
total of 1,061 participants with T2DM were finally recruited. 
The Institutional Review Board at Severance Hospital approved 
this study protocol (4-2017-0667). Written informed consent was 
waived because the database was accessed only for analysis pur-
poses and personal information was not used.
Measurement of blood glucometabolic parameters
After the subjects fasted overnight, blood samples were col-
lected before (0 minute, designated as basal) and after (90 min-
utes, designated as stimulated) participants ingested two cans 
(total 400 mL, 400 kcal, 18 g fat, 44 g carbohydrate, and 20 g 
protein) of a standardized mixed meal (Mediwell Diabetic 
Meal; Meail Dairies Co., Yeongdong, Korea) to measure glu-
cose and insulin/C-peptide levels and to perform other chem-
istry tests. The homeostasis model assessment of β-cell 
(HOMA-β) was calculated as 20×fasting insulin level (mIU/
mL)/[fasting plasma glucose (mg/dL)–3.5]. The homeostasis 
model assessment of insulin resistance (HOMA-IR) was calcu-
lated as fasting plasma glucose (mg/dL)×fasting insulin (mIU/
mL)/22.5 [8]. The eGFR was derived from the Chronic Kidney 
Disease Epidemiology Collaboration equation [9]. HbA1c was 
measured by immunoassay using an Integra 800 CTS (Roche, 
Hercules, CA, USA). Serum GA level was determined by an 
enzymatic method (Lucica GA-L; Asahi Kasei Pharma Co., 
Tokyo, Japan) using a Hitachi 7600 autoanalyzer (Hitachi Ltd., 
Tokyo, Japan). Serum glucose and creatinine were also mea-
sured using the Hitachi 7600 analyzer. For serum creatinine, a 
compensated kinetic Jaffe method (Clinimate CRE; Sekisui 
Medical Co. Ltd., Tokyo, Japan) was used in which the creati-
nine level was standardized by isotope dilution mass spec-
trometry. Serum insulin and C-peptide were measured with an 
electrochemiluminescence immunoassay (Cobas® e601 ana-
lyzer; Roche Diagnostics, Basel, Switzerland).
Measurement of urinary glomerular and tubular damage 
markers
Urinary NAG, albumin, glucose, and creatinine levels were 
measured from the fasting morning spot urine sample ob-
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tained from each participant. Urinary NAG, albumin, and glu-
cose levels were expressed as uNAG-to-creatinine ratio and 
ACR to minimize the influence of variance in kidney function. 
Urinary NAG activity was considered abnormal when >5.8 U/
g creatinine [10]. Urinary NAG was measured using a reagent 
from Nittobo Medial Co. Ltd. (Tokyo, Japan) and a JCA-BM 
6010/c automated chemistry analyzer (JEOL Ltd., Tokyo, Ja-
pan). Urine-albumin level was measured via the immunotur-
bidimetric method using an AU680 automated chemistry ana-
lyzer (Beckman Coulter Inc., Brea, CA, USA). Urine-creati-
nine level was also measured with an AU680 analyzer using 
the kinetic Jaffe method.
Statistical analysis
A normality test was performed on all continuous variables. 
The data are presented as mean±standard deviation for nor-
mally distributed continuous variables and median (interquar-
tile range) for non-normally distributed continuous variables. 
Categorical data are expressed as number and percentage. The 
characteristics of the study participants were analyzed accord-
ing to uNAG level using the two-sample Student t-test for con-
tinuous variables and the chi-square test for categorical vari-
ables. Correlations between uNAG and other parameters were 
analyzed with Pearson correlation analysis. Stepwise multiple 
linear regression analysis was performed on logarithm-trans-
formed uNAG values to model the relationships between 
uNAG and glycemic parameters. To correct for skewed distri-
butions, non-normally distributed continuous variables, such 
as urinary ACR, were logarithmically transformed before sta-
tistical analysis. Receiver operating characteristic (ROC) curve 
analysis was conducted to evaluate the capacity to discriminate 
between glycemic parameters, such as GA, HbA1c, stimulated 
glucose, and fasting glucose, to predict the presence of renal 
tubular dysfunction. The area under the curve (AUC) was cal-
culated using binary logistic regression, and statistical com-
parisons of the AUCs among glycemic parameters followed 
the DeLong method [11]. All data analyses were performed 
using SPSS version 20.0 (IBM Co., Armonk, NY, USA). P val-
ues <0.05 were considered significant. 
RESULTS
Characteristics of the study participants
Mean age of the study population was 60.14±11.37 years, and 
55.6% were men. Due to our inclusion criteria (ACR <30 mg/g 
and eGFR ≥60 mL/min/1.73 m2), mean eGFR and ACR were 
91.17±15.33 mL/min/1.73 m2 and 7.59 mg/g (interquartile 
range [IQR], 4.54 to 12.47 mg/g), respectively. Based on a pre-
vious finding of Japanese nondiabetic subjects that states the 
normal reference range for uNAG as 1.6 to 5.8 U/g Cr (creati-
nine) [10], we arbitrary classified subjects into a normal uNAG 
group and a high group (normal vs. high [>5.8 U/g Cr]) (Table 
1). The median uNAG values among participants with normal 
and high uNAG levels were 3.99 U/g Cr (IQR, 2.82 to 4.96 U/g 
Cr) and 9.48 U/g Cr (IQR, 7.38 to 13.51 U/g Cr), respectively. 
Participants with high uNAG level were significantly less likely 
to be obese or more likely to be older, had longer duration of 
diabetes, and higher level of low density lipoprotein cholesterol 
(LDL-C) compared with normal uNAG subjects. Blood pres-
sure did not differ between the two groups. Regarding gluco-
metabolic parameters, subjects with high uNAG level had sig-
nificantly higher levels of fasting glucose (133.15±32.96 vs. 
141.20±45.31, P=0.001), stimulated plasma glucose (181.10± 
50.78 vs. 202.87±64.85, P<0.001), δ glucose (49.80±39.96 vs. 
60.44±43.64, P=0.001), GA (17.42%±4.18% vs. 19.65%±5.99%, 
P<0.001), and HbA1c (7.04%±1.05% vs. 7.41%±1.38%, P< 
0.001) than subjects with normal uNAG level. Participants 
with high uNAG level had lower levels of stimulated C-peptide 
(5.52±2.39 vs. 4.95±2.21, P=0.002), δ C-peptide (3.13±1.94 
vs. 2.67±1.71, P=0.001), and HOMA-β (48.09 [IQR, 31.71 to 
74.74] vs. 39.09 [IQR, 23.74 to 63.93], P<0.001) than partici-
pants with normal uNAG level, whereas HOMA-IR levels were 
not different between the two groups. 
Correlations between uNAG and glucose parameters
In Pearson correlation analysis, uNAG was positively signifi-
cantly correlated with ACR (r=0.233, P<0.001), but not with 
eGFR (r=0.044, P=0.154). Urinary NAG was also positively 
associated with fasting and stimulated glucose, stimulated C-
peptide, δ C-peptide, GA, and HbA1c. Among the various 
glucometabolic variables, GA had a stronger relationship with 
uNAG than HbA1c (r=0.259, P<0.001 vs. r=0.197, P<0.001) 
(Table 2). We also evaluated the independent associations be-
tween glucose parameters and uNAG as a renal tubulopathy 
marker, for which we performed multiple linear regression 
analyses (Table 3). In model 1, after adjusting for confounding 
factors, such as age, sex, body mass index, diabetes duration, 
and current smoking, GA was independently associated with 
uNAG level (standardized β=0.276, P<0.001), whereas HbA1c 
was not (standardized β=–0.033, P=0.539). After further ad-
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Table 1. Baseline characteristics of study subjects according to urinary NAG levels
Characteristic All Normal urinary NAG  (≤5.8 U/g Cr)
High urinary NAG  
(>5.8 U/g Cr) P value
Number 1,061 431 630
Demographic
   Age, yr 60.14±11.37 57.42±11.31 62.00±11.03 <0.001
   Male sex 593 (55.61) 268 (62.3) 325 (51.6) 0.002
   BMI, kg/m2 25.03±3.68 25.39±3.39 24.78±3.85 0.009
   Current smoker 162 (15.27) 70 (16.3) 92 (14.6) 0.487
   Diabetes duration, yr 8.33±7.56 6.94±6.78 9.28±7.91 <0.001
   Systolic blood pressure, mm Hg 123.79±15.09 124.68±14.80 123.18±15.27 0.115
   Diastolic blood pressure, mm Hg 76.22±20.51 77.15±11.36 75.57±24.92 0.220
Glucometabolic parameter
   Fasting glucose, mg/dL 137.93±40.91 133.15±32.96 141.20±45.31 0.001
   Stimulated glucose, mg/dL 195.07±61.05 181.10±50.78 202.87±64.85 <0.001
   δ Glucose, mg/dL 56.63±43.64 49.80±39.96 60.44±43.64 0.001
   HbA1c, % 7.26±1.27 7.04±1.05 7.41±1.38 <0.001
   Glycated albumin, % 18.75±5.44 17.42±4.18 19.65±5.99 <0.001
   Glycated albumin to HbA1c 2.55±0.43 2.45±0.36 2.62±0.47 <0.001
   Fasting C-peptide, ng/mL 2.27±1.03 2.33±1.01 2.23±1.04 0.128
   Stimulated C-peptide, ng/mL 5.16±2.29 5.52±2.39 4.95±2.21 0.002
   δ C-peptide, ng/mL 2.83±1.81 3.13±1.94 2.67±1.71 0.001
   HOMA-β 42.07 (26.23–67.08) 48.09 (31.71–74.74) 39.09 (23.74–63.93) <0.001
   HOMA-IR 2.59 (1.63–4.21) 2.67 (1.71–4.18) 2.58 (1.57–4.24) 0.299
Nephropathic indice
   eGFR, mL/min/1.73 m2 91.17±15.33 90.98±14.97 91.30±15.59 0.736
   Urinary NAG, U/g creatinine 6.66 (4.44–10.47) 3.99 (2.82–4.96) 9.48 (7.38–13.51) <0.001
   Urinary ACR, mg/g 7.59 (4.54–12.47) 6.16 (4.04–10.03) 8.68 (5.31–14.65) <0.001
Biochemistry profile
   Albumin, mg/dL 4.35±0.31 4.43±0.28 4.29±0.31 <0.001
   Total cholesterol, mg/dL 160.57±37.02 157.69±34.89 162.55±38.31 0.036
   Triglyceride, mg/dL 112 (80–158.25) 113.5 (80–157) 111 (80–159.75) 0.977
   HDL-C, mg/dL 49.81±13.69 50.68±14.39 49.22±13.16 0.090
   LDL-C, mg/dL 79.07±33.19 74.24±31.73 82.38±33.79 <0.001
Antidiabetic drug
   Insulin 132 (12.44) 46 (10.7) 86 (13.7) 0.156
   Metformin 818 (77.10) 325 (75.4) 493 (78.3) 0.298
   DPP-4 inhibitor 542 (51.08) 206 (47.8) 336 (53.3) 0.080
   Thiazolidinedione 61 (5.7) 13 (3) 48 (7.6) 0.002
   Sulfonylurea 340 (32.05) 113 (26.2) 227 (36) 0.001
   Diuretics 57 (5.37) 24 (5.6) 33 (5.2) 0.890
   ACE inhibitor or ARB 326 (30.73) 141 (32.7) 185 (29.4) 0.278
Values are presented as mean±standard deviation, number (%), or median (interquartile range).
NAG, N-acetyl-β-d-glucosaminidase; BMI, body mass index; HbA1c, glycosylated hemoglobin; HOMA-β, homeostasis model assessment of 
β-cell; HOMA-IR, homeostasis model assessment of insulin resistance; eGFR, estimated glomerular filtration rate; ACR, albumin-to-creatinine 
ratio; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; DPP-4, dipeptidyl peptidase-4; ACE, angioten-
sin converting enzyme; ARB, angiotensin receptor blocker.
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justment for other confounding variables, including fasting 
glucose, stimulated glucose, stimulated C-peptide, δ C-pep-
tide, eGFR, LDL-C, albumin, and log-transformed urinary 
ACR (model 2), GA was still significantly associated with uNAG 
level (standardized β=0.217, P=0.014), whereas HbA1c and 
stimulated glucose were not. This trend remained statistically 
significant even after additional adjustments for sulfonylurea 
use, insulin use, angiotensin converting enzyme inhibit or, an-
giotensin receptor blocker use, and diuretic use (model 3). 
GA for predicting renal tubular damage in T2DM 
The ability of glycemic parameters, such as serum GA, HbA1c, 
stimulated glucose, and fasting glucose, to discriminate the 
presence of renal tubular damage in patients with T2DM who 
have normoalbuminuria and normal eGFR was assessed by 
comparing the AUCs from ROC analyses (Fig. 1). The AUC 
values for all four glycemic parameters were statistically signif-
icant. The AUC for renal tubular damage of GA was signifi-
cantly higher (0.634; 95% confidence interval [CI], 0.646 to 
0.899; P<0.001) than the AUC of HbA1c (0.598; 95% CI, 0.553 
to 0.640; P<0.001), stimulated glucose (0.594; 95% CI, 0.552 to 
0.636; P<0.001), and fasting glucose (0.558; 95% CI, 0.515 to 
0.600; P= 0.01). The optimal GA cutoff point for renal tubular 
damage was 17.55%. The sensitivity and specificity at this level 
were 59% and 62%, respectively.
DISCUSSION
Accumulating evidence indicates that GA has greater clinical 
relevance than HbA1c for evaluating glucose fluctuation and 
for predicting vascular complications in patients with T1DM 
and T2DM [12,13]. However, the optimal interpretation of GA 
in the context of early diabetic nephropathy, especially renal 
tubular damage, has not been fully evaluated. Based on previ-
Table 2. Correlation between urinary NAG and demographic 
and glycometabolic parameters 
Parameter Urinary NAG/Cr, U/g creatinine
a
r P value
Age, yr 0.227 <0.001
Body mass index, kg/m2 –0.069 0.025
Fasting glucose, mg/dL 0.124 <0.001
Stimulated glucose, mg/dL 0.185 <0.001
Fasting C-peptide, ng/mL 0.001 0.974
Stimulated C-peptide, ng/mL –0.115 0.002
δ C-peptide, nmol/L –0.153 <0.001
Glycated albumin, % 0.259 <0.001
HbA1c, % 0.197 <0.001
HOMA-βa –0.060 0.098
HOMA-IRa 0.029 0.423
Urinary ACR, mg/ga 0.233 <0.001
eGFR, mL/min/1.73 m2 0.044 0.154
NAG, N-acetyl-β-d-glucosaminidase; Cr, creatinine; r, correlation co-
efficient; HbA1c, glycosylated hemoglobin; HOMA-β, homeostasis 
model assessment of β-cell; HOMA-IR, homeostasis model assess-
ment of insulin resistance; ACR, albumin-to-creatinine ratio; eGFR, 
estimated glomerular filtration rate.
aLog transformed form.
Table 3. Multiple linear regression models for urinary NAG in type 2 diabetes mellitus 
Variable
Model 1a Model 2b Model 3c
STD β P value STD β P value STD β P value
Glycated albumin, % 0.276 <0.001 0.217 0.014 0.213 0.016
HbA1c, % –0.002 0.968 –0.135 0.096 –0.137 0.096
Fasting glucose, mg/dL - - –0.003 0.962 0.006 0.930
Stimulated glucose, mg/dL - - 0.100 0.115 0.095 0.140
Stimulated C-peptide, ng/mL - - 0.176 0.103 0.152 0.171
δ C-peptide, ng/mL - - –0.226 0.028 –0.206 0.050
Logarithm-transformed values of urinary NAG were used for analysis.
NAG, N-acetyl-β-d-glucosaminidase; STD β, standardized β coefficient; HbA1c, glycosylated hemoglobin. 
aModel 1: adjusted age, sex, body mass index, diabetes duration, and current smoking, bModel 2: model 1+further adjusted fasting glucose, 
stimulated glucose, stimulated C-peptide, δ C-peptide, estimated glomerular filtration rate, low density lipoprotein cholesterol, albumin, and 
urinary albumin-to-creatinine ratio (log transformed), cModel 3: model 2+further adjusted sulfonylurea use, insulin use, angiotensin convert-
ing enzyme inhibitor or angiotensin receptor blocker use, and diuretics use. 
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ous findings that uNAG might be a more sensitive urinary bio-
marker than urinary ACR for early DKD detection, as well as 
its association with postprandial glucose and GA in patients 
with T2DM, we hypothesized that GA, which more sensitively 
reflects increases in blood glucose excursions than HbA1c, es-
pecially postprandial glucose, might signal renal tubular dam-
age earlier in the subclinical stage of DKD. To test this hypoth-
esis, we investigated various glucometabolic parameters and 
kidney-damage markers in patients with T2DM with normo-
albuminuria (ACR <30 mg/g) and normal eGFR (≥60 mL/
min/1.73 m2) who were recruited from three hospital databas-
es. We focused on the association between GA and uNAG ex-
cretion and observed that GA was significantly associated with 
uNAG excretion independent of other confounding factors, 
but that HbA1c was not. Furthermore, we observed that GA 
can better discriminate early renal tubular dysfunction using 
AUC comparison analysis. These findings suggest that GA can 
be a more reliable marker than HbA1c or fasting plasma glu-
cose for detecting early renal tubular damage in patients with 
T2DM without overt DKD.
DKD not only occurs in 20% to 40% of all patients with dia-
betes, but it is also one of the major end-organ complications 
of diabetes and continues to be the most common cause of 
end-stage renal disease [14]. 
Regarding DKD, growing evidence suggests that some pa-
tients with diabetic nephropathy display neither substantial 
glomerular pathology nor proteinuria and that kidney func-
tion commonly assessed by eGFR declines well before tradi-
tional indicators of kidney disease, such as albuminuria. This 
might indicate that changes in the glomerulus are neither the 
initial events of DKD development nor the major determinant 
of renal prognosis in subjects with T2DM. Furthermore, it is 
now increasingly recognized that tubules play an important 
role in DKD pathogenesis. In the context of DKD, it is well 
known that uNAG is markedly elevated, even in patients with 
normal to mildly increased albuminuria, notwithstanding that 
it is also higher in patients with more aggravated albuminuria 
[4]. Thus, to examine the associations between various glyce-
mic parameters and early renal damage in patients with 
T2DM, we adopted uNAG as an early tubulopathy marker.
Many previous studies have demonstrated that intensive gly-
cemic control can delay the onset and progression of DKD in 
patients with T2DM [15,16]. Measurement of HbA1c is gener-
ally considered the gold standard index for glycemic control. 
Because periodic monitoring of HbA1c level can be informa-
tive for evaluating the degree of glycemic control in patients 
with diabetes, it is possible to assess the relationship between 
glycemic control and development of diabetes-related compli-
cations using these measures. However, GA is now gaining 
popularity as an index of glycemic control during intensive 
treatment. GA is not affected by hemoglobin level and is supe-
rior to HbA1c as a representation of short-term glycemic con-
trol. Furthermore, recent studies have reported that GA is a 
better reflection of glycemic excursions and postprandial hy-
perglycemia compared with HbA1c in various clinical settings 
[5,17-19]. From this background, some studies have demon-
strated that GA as well as the GA-to-HbA1c ratio, but not 
HbA1c alone, were associated with carotid intima media 
thickness or plaque and severity of coronary atherosclerosis 
[20,21]. In terms of DKD, several studies have concluded that 
mean GA level, rather than mean HbA1c level, is more closely 
associated with DKD progression [12,22]. However, these 
studies included individuals with a broad range of renal im-
pairment (normal to advanced CKD) and a broad range of al-
Fig. 1. Receiver operating characteristic curve of glucose pa-
rameters for predicting the renal tubulopathy in subjects with 
diabetes with normal renal function and normoalbuminuria. 
GA, glycated albumin; HbA1c, glyco sylated hemoglobin; CI, 
confidence interval.
Area under 
the curve 95% CI P value
P value 
vs. GA
GA 0.634 0.592–0.675 <0.001 -
HbA1c 0.598 0.553–0.640 <0.001 0.027
Stimulated glucose 0.594 0.552–0.636 <0.001 0.05
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buminuria (normal to macroalbuminuria). Although cumula-
tive evidence supports GA’s predictive role for microvascular 
complications, the relationship between GA and early renal tu-
bular dysfunction in patients with T2DM has not yet been 
evaluated. Thus, to investigate the predictive ability of various 
glycemic parameters for early renal tubular dysfunction among 
patients with T2DM without overt DKD, we included subjects 
who had normal eGFR (≥60 mL/min/1.73 m2) and normoal-
buminuria (urine ACR ≤30 mg/g).
The major interest of this study was the association between 
GA and renal tubular marker independently of HbA1c and 
other confounding factors. We restricted our subjects to those 
without overt CKD to minimize the possibility of confounding 
with CKD characteristics, such as albumin excretion or hema-
tologic alteration. Consequently, our results suggest that GA 
can be a strong independent predictor of early renal tubular 
damage, beyond its role as a surrogate marker of glucose con-
trol. Because our study did not directly measure oxidative stress 
markers, degree of glucose excursion, or inflammation, the 
mechanisms underlying the close relationship between GA 
and early renal tubular dysfunction remain unclear. One possi-
bility is that, since glycation of albumin impairs the antioxidant 
activities of albumin, GA can contribute to increased oxidative 
stress in patients with diabetes [7] and, in turn, induces tubular 
injury. Furthermore, because GA has not only been shown to 
be a marker of postprandial glycemic excursion, but also has 
been postulated to promote atherosclerosis, GA can indepen-
dently influence diabetes microvascular complications [23]. 
With respect to glucometabolic parameters, recent studies 
have shown that impaired insulin secretory function, which 
might be complexly influenced by T2DM duration in cases in 
which β-cell function gradually decreases over time, is more 
sensitively reflected by GA than by HbA1c. Additionally, GA 
was statistically more strongly associated with diabetes dura-
tion than HbA1c [24]. Consistent with previous findings, our 
data demonstrated that uNAG was significantly associated 
with insulin secretory function as presented as C-peptide val-
ues (Table 3, Model 2, 3). This suggests that impaired insulin 
secretory function might have a role in early renal tubular dys-
function of DKD. These findings could explain GA’s strong in-
volvement in the pathogenesis of major diabetic complications 
and the identification of people at risk for microvascular com-
plications.
In terms of GA’s value for predicting renal tubular dysfunc-
tion, we concluded that the optimal cutoff point was 17.55%. 
Although several studies have reported that GA is associated 
with a higher risk of diabetes complications, few studies have 
investigated GA cutoff values for predicting chronic complica-
tion in participants with diabetes. One recent study demon-
strated that the GA cutoff value for predicting overall survival 
in subjects with diabetes undergoing hemodialysis was 18.6% 
(sensitivity 73%, specificity 67%) [25]. Selvin et al. [26] report-
ed that GA >23% was significantly associated with diabetic 
retinopathy in the ARIC (Atherosclerosis Risk in Communi-
ties) study. The optimal GA cutoff point for predicting renal 
tubulopathy in our study was lower. Our lower cutoff point can 
be explained by the fact that we excluded subjects with overt 
DKD. Considering that GA has been considered a good indi-
cator of diabetes complications, further large-scale prospective 
studies might be warranted to determine the GA cutoff value 
for predicting early renal tubular dysfunction in subjects with-
out overt CKD.
This study has several limitations. First, our analysis includ-
ed only cross-sectional data; we were therefore unable to deter-
mine a causal relationship between GA level and either initia-
tion or progression of diabetic tubulopathy. Second, we could 
not collect complete data about medicinal intake that could af-
fect kidney function, such as nonsteroidal anti-inflammatory 
drugs. Finally, we did not assess the associations between gly-
cemic indices and renal tubulopathy using other renal tubular 
damage markers, like kidney injury molecule 1 or liver fatty-
acid binding protein [27].
Collectively, this study suggests that GA level might be a 
good predictor of renal tubulopathy in patients with T2DM 
without overt DKD, regardless of HbA1c level or other con-
ventional risk factors. Moreover, we demonstrated that GA has 
better discriminatory capacity for renal tubular dysfunction 
than HbA1c. These findings indicate that GA monitoring, 
rather than HbA1c monitoring, is most useful for detecting 
higher risk of diabetes-induced tubulopathy as an early disease 
event that contributes to CKD development in patients with 
T2DM. Further large-scale prospective studies might be war-
ranted to generalize the relationship between GA and renal tu-
bular damage in patients with T2DM with overt albuminuria 
or impaired renal function.
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